Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Decoy Therapeutics Inc.FLKS · Entity 937 | Chief Financial Officer | June 14, 2018 | June 18, 2018 |
| Oncorus, Inc.ONCR · Entity 112213 | CFO and Treasurer | March 01, 2022 | March 02, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Decoy Therapeutics Inc.
Report date June 14, 2018 · Filed June 18, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.35 · Expires 2028-06-14 | Direct | 179,848 |
Reported balance
After 2018-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-14 · Grant · Acquired 179,848 · Balance 179,848 F1: The stock option will vest in 48 successive equal monthly installments measured from June 14, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest in 48 successive equal monthly installments measured from June 14, 2018.
Oncorus, Inc.
Report date March 01, 2022 · Filed March 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2032-02-29 | Direct | 90,000 |
Reported balance
After 2022-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-01 · Grant · Acquired 90,000 · Balance 90,000 F1: Twenty-five percent (25%) of the shares subject to the option shall vest on March 1, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person's continued service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Twenty-five percent (25%) of the shares subject to the option shall vest on March 1, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person's continued service through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2022 Filed Mar 2, 2022 16:40 UTC | Oncorus, Inc. ONCR · Entity 112213 | GrantEmployee Stock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014780 · doc4.xml · derivative · entry 1 McCabe John P. · CIK 0001630720 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2032-02-29 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on March 1, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:14 UTC | Oncorus, Inc. ONCR · Entity 112213 | GrantEmployee Stock Option (right to buy) · Derivative | 76,894 | $0.00 Strike: $15.85 | $0.00 |
DisclosureSEC source: 0001209191-21-017203 · doc4.xml · derivative · entry 1 McCabe John P. · CIK 0001630720 · CFO, Treasurer and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,894 Underlying: Common Stock · 76,894 shares Expires 2031-02-28 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on March 1, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:14 UTC | Decoy Therapeutics Inc. FLKS · Entity 937 | GrantStock Option (right to buy) · Derivative | 179,848 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001615219-18-000038 · wf-form4_152935285457366.xml · derivative · entry 1 McCabe John P. · CIK 0001630720 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,848 Underlying: Common Stock · 179,848 shares Expires 2028-06-14 F1 · derivative.exercise_date: The stock option will vest in 48 successive equal monthly installments measured from June 14, 2018. Read SEC document |
| January 17, 2018 Filed Jan 19, 2018 15:00 UTC | Decoy Therapeutics Inc. FLKS · Entity 937 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.98 | $0.00 |
DisclosureSEC source: 0001615219-18-000005 · wf-form4_151637400432045.xml · derivative · entry 1 McCabe John P. · CIK 0001630720 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-01-17 F1 · derivative.exercise_date: The stock option will vest in 48 successive equal monthly installments measured from January 17, 2018. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 14:03 UTC | Decoy Therapeutics Inc. FLKS · Entity 937 | GrantStock Option (right to buy) · Derivative | 67,000 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0001615219-17-000009 · wf-form4_148492099847637.xml · derivative · entry 1 McCabe John P. · CIK 0001630720 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2027-01-18 F1 · derivative.exercise_date: The stock option will vest in 48 successive equal monthly installments measured from January 18, 2017. Read SEC document |
| November 07, 2016 Filed Nov 7, 2016 21:40 UTC | Decoy Therapeutics Inc. FLKS · Entity 937 | PurchaseCommon Stock | 1,650 | $6.01 | $9,916.50 |
DisclosureSEC source: 0001615219-16-000228 · wf-form4_147855482137744.xml · nonDerivative · entry 1 McCabe John P. · CIK 0001630720 · VP of Finance & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,650 F1 · price: The price in Column 4 is a weighted average purchase price. The prices actually received ranged from $5.99 to $6.01. The reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.